BR0215148A - Composições farmacêuticas de agonista parcial 5ht4 - Google Patents

Composições farmacêuticas de agonista parcial 5ht4

Info

Publication number
BR0215148A
BR0215148A BR0215148-0A BR0215148A BR0215148A BR 0215148 A BR0215148 A BR 0215148A BR 0215148 A BR0215148 A BR 0215148A BR 0215148 A BR0215148 A BR 0215148A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
partial agonist
weight
amount
agonist pharmaceutical
Prior art date
Application number
BR0215148-0A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0215148A publication Critical patent/BR0215148A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSIçõES FARMACêUTICAS DE AGONISTA PARCIAL 5HT4". A presente invenção refere-se a uma composição farmacêutica sólida para administração oral compreendendo tegaserod em forma de base ou sal em uma quantidade de até 10% em peso e um agente de massa em uma quantidade de 70 a 90% em peso, um desintegrante em uma quantidade de menos que 15% em peso, um agente de deslizamento e um lubrificante.
BR0215148-0A 2001-12-21 2002-12-20 Composições farmacêuticas de agonista parcial 5ht4 BR0215148A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0215148A true BR0215148A (pt) 2004-10-19

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215148-0A BR0215148A (pt) 2001-12-21 2002-12-20 Composições farmacêuticas de agonista parcial 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (pt)
EP (2) EP1321142A1 (pt)
JP (1) JP4718776B2 (pt)
KR (1) KR100980144B1 (pt)
CN (1) CN100464749C (pt)
AR (1) AR037937A1 (pt)
AT (1) ATE320807T1 (pt)
AU (1) AU2002361198B2 (pt)
BR (1) BR0215148A (pt)
CA (1) CA2470668C (pt)
CO (1) CO5640102A2 (pt)
CY (1) CY1105559T1 (pt)
DE (1) DE60210139T2 (pt)
DK (1) DK1458377T3 (pt)
EC (1) ECSP105163A (pt)
EG (1) EG24194A (pt)
ES (1) ES2258171T3 (pt)
HU (1) HU226589B1 (pt)
IL (2) IL162451A0 (pt)
MX (1) MXPA04006157A (pt)
MY (1) MY139546A (pt)
NO (1) NO20042779L (pt)
NZ (1) NZ533585A (pt)
PE (1) PE20030872A1 (pt)
PL (1) PL369509A1 (pt)
PT (1) PT1458377E (pt)
RU (1) RU2322978C2 (pt)
SI (1) SI1458377T1 (pt)
TW (1) TWI260221B (pt)
WO (1) WO2003053432A1 (pt)
ZA (1) ZA200404467B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228179B1 (en) * 1998-08-21 2013-01-28 Novartis Ag Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
SG146608A1 (en) 2003-09-12 2008-10-30 Amgen Inc Dw Us Rapid dissolution formulation of a calcium receptor-active compound
EP1594493A2 (en) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2384318T3 (pl) 2008-12-31 2018-04-30 Ardelyx, Inc. Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego
EP2887964B1 (en) 2012-08-21 2019-07-03 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
RS58969B1 (sr) 2013-04-12 2019-08-30 Ardelyx Inc Jedinjenja koja se vezuju za nhe3 i postupci za inhibiranje transporta fosfata
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
HU228179B1 (en) * 1998-08-21 2013-01-28 Novartis Ag Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.

Also Published As

Publication number Publication date
DK1458377T3 (da) 2006-06-12
KR20040066922A (ko) 2004-07-27
EP1458377A1 (en) 2004-09-22
CO5640102A2 (es) 2006-05-31
ES2258171T3 (es) 2006-08-16
IL162451A0 (en) 2005-11-20
NO20042779L (no) 2004-09-17
IL162451A (en) 2009-02-11
JP4718776B2 (ja) 2011-07-06
TWI260221B (en) 2006-08-21
CA2470668A1 (en) 2003-07-03
RU2004122631A (ru) 2005-08-10
RU2322978C2 (ru) 2008-04-27
TW200410684A (en) 2004-07-01
US20050106236A1 (en) 2005-05-19
MY139546A (en) 2009-10-30
DE60210139T2 (de) 2006-08-17
EP1458377B1 (en) 2006-03-22
PL369509A1 (en) 2005-04-18
HUP0402492A2 (hu) 2005-07-28
AU2002361198A1 (en) 2003-07-09
AR037937A1 (es) 2004-12-22
AU2002361198B2 (en) 2006-06-08
NZ533585A (en) 2006-04-28
PT1458377E (pt) 2006-07-31
CN100464749C (zh) 2009-03-04
US20090104263A1 (en) 2009-04-23
PE20030872A1 (es) 2003-11-24
ATE320807T1 (de) 2006-04-15
CA2470668C (en) 2011-07-05
HUP0402492A3 (en) 2008-04-28
ZA200404467B (en) 2006-05-31
EP1321142A1 (en) 2003-06-25
MXPA04006157A (es) 2004-10-27
CN1606438A (zh) 2005-04-13
CY1105559T1 (el) 2010-07-28
EG24194A (en) 2008-10-14
JP2005516946A (ja) 2005-06-09
SI1458377T1 (sl) 2006-08-31
KR100980144B1 (ko) 2010-09-03
ECSP105163A (es) 2010-07-30
HU226589B1 (en) 2009-04-28
WO2003053432A1 (en) 2003-07-03
DE60210139D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
BR0215148A (pt) Composições farmacêuticas de agonista parcial 5ht4
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
BR0204001A (pt) Forma de dosagem oral sólida de simeticona
BR9802487A (pt) Composicões de simeticona/fosfato de cálcio anídrico.
BR0317392A (pt) Formulação não-higroscópica incluindo uma droga higroscópica
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
BRPI0409250B8 (pt) Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
CY1118179T1 (el) Φαρμακευτικη συνθεση
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BRPI0412489A (pt) composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima
MX2007004294A (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0114727A (pt) Método para suprimir o mau odor oral e prover proteção de hálito duradoura na cavidade oral
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
BR9810658A (pt) Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna.
BR0316906A (pt) administração do capsaicinoides
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
MXPA04001250A (es) Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/404; A61K 9/20; A61P 1/00

Ipc: A61K 31/404 (2011.01), A61K 9/20 (2011.01), A61P 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.